RBC Capital Upgrades Sagent Pharmaceuticals (SGNT) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St set to open higher after inflation data, earnings boost
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Sagent Pharmaceuticals (SGNT) Numbers Cut at Piper Jafffray Post Q2
August 5, 2015 9:47 AM EDTPiper Jaffray analyst David Amsellem lowered his price target on Sagent Pharmaceuticals (NASDAQ: SGNT) to $32.00 (from $35.00) following Q2 results but maintained an Overweight rating.
Amsellem commented, "This morning, Sagent reported a 2Q15 net loss per share of ($0.01), compared to the Street EPS... More
Sagent Pharmaceuticals (SGNT) Misses Q2 EPS by 6c
August 4, 2015 8:54 AM EDTSagent Pharmaceuticals (NASDAQ: SGNT) reported Q2 EPS of ($0.01), $0.06 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $77.3 million versus the consensus estimate of $83.28 million.
For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.
... More